Document Detail


Vascular dysfunction in chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  19542477     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Cardiovascular disease is a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD), which may in part be attributable to abnormalities of systemic vascular function. It is unclear whether such associations relate to the presence of COPD or prior smoking habit. OBJECTIVES: To undertake a comprehensive assessment of vascular function in patients with COPD and healthy control subjects matched for smoking history. METHODS: Eighteen men with COPD were compared with 17 healthy male control subjects matched for age and lifetime cigarette smoke exposure. Participants were free from clinically evident cardiovascular disease. MEASUREMENTS AND MAIN RESULTS: Pulse wave velocity and pulse wave analysis were measured via applanation tonometry at carotid, radial, and femoral arteries. Blood flow was measured in both forearms using venous occlusion plethysmography during intrabrachial infusion of endothelium-dependent vasodilators (bradykinin, 100-1,000 pmol/min; acetylcholine, 5-20 microg/min) and endothelium-independent vasodilators (sodium nitroprusside, 2-8 microg/min; verapamil, 10-100 microg/min). Tissue plasminogen activator (t-PA) was measured in venous plasma before and during bradykinin infusions. Patients with COPD have greater arterial stiffness (pulse wave velocity, 11 +/- 2 vs. 9 +/- 2 m/s; P = 0.003; augmentation index, 27 +/- 10 vs. 21 +/- 6%; P = 0.028), but there were no differences in endothelium-dependent and -independent vasomotor function or bradykinin-induced endothelial t-PA release (P > 0.05 for all). CONCLUSIONS: COPD is associated with increased arterial stiffness independent of cigarette smoke exposure. However, this abnormality is not explained by systemic endothelial dysfunction. Increased arterial stiffness may represent the mechanistic link between COPD and the increased risk for cardiovascular disease associated with this condition.
Authors:
John D Maclay; David A McAllister; Nicholas L Mills; Finny P Paterson; Christopher A Ludlam; Ellen M Drost; David E Newby; William Macnee
Related Documents :
3725627 - Two-dimensional echocardiographic assessment of adequacy of pulmonary artery banding.
8908227 - Pulmonary vascular effects of nitroglycerin and isosorbide dinitrate in patients with e...
3655977 - Pulmonary vascular disease in ventricular septal defect: structural and functional corr...
21509297 - Retrieval of dislodged central venous pressure catheters: early experience with three c...
20587277 - Strategy for the treatment of acute thromboembolic stroke involving an internal carotid...
10881857 - The stomach as a microvascularly augmented flap for esophageal replacement.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-19
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  180     ISSN:  1535-4970     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-07     Completed Date:  2009-10-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  513-20     Citation Subset:  AIM; IM    
Affiliation:
Centre for Inflammation Research, Edinburgh University, Edinburgh, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Arteries / physiopathology
Blood Flow Velocity / physiology*
Cardiovascular Diseases / physiopathology*
Case-Control Studies
Endothelium / physiology
Fibrinolysis / physiology
Forced Expiratory Volume / physiology
Humans
Male
Middle Aged
Plethysmography
Pulmonary Disease, Chronic Obstructive / physiopathology*
Pulsatile Flow / physiology
Risk Factors
Smoking
Tissue Plasminogen Activator / blood
Vascular Resistance / physiology
Grant Support
ID/Acronym/Agency:
//Chief Scientist Office
Chemical
Reg. No./Substance:
EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections
Comment In:
Am J Respir Crit Care Med. 2009 Sep 15;180(6):487-8   [PMID:  19734349 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
Next Document:  Early daycare is associated with an increase in airway symptoms in early childhood but is no protect...